NCT02826681View on ClinicalTrials.gov

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

September 4, 2021

Study Completion Date

July 1, 2022

Conditions
Restless Legs Syndrome (RLS)
Interventions
DRUG

Injectafer® (Ferric Carboxymaltose - FCM)

Intravenous Iron

DRUG

Placebo (Normal Saline)

Normal Saline Solution

Trial Locations (8)

32801

CNS Healthcare, Orlando

33912

Alliance for Multispeciality Research, Fort Myers

77074

Clinical Trial Network, Houston

89128

Neurology Center of Las Vegas, Las Vegas

91945

Synergy San Diego, Lemon Grove

98104

The Polyclinic, Seattle

21224-2780

Johns Hopkins Bayview Medical Center, Baltimore

02169

Boston Neuro Research, South Dartmouth

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT02826681 - Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia | Biotech Hunter | Biotech Hunter